A Phase 3 interventional study of VER-01 and Placebo in Chronic Non-specific Low Back Pain, sponsored by Vertanical GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.
Sponsored by Vertanical GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.
Among the 59 studies in Low Back Pain with a site in Germany, this one is the 2nd largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 43rd registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
University Hospital Augsburg · Sites in Germany
Ages 18+
ZygoFix · Sites in Germany, Italy
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 17 · Phase 4 4
First in 2003; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 820 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 128 across the 54 interventional studies, 102 across the 5 observational. Of the 47 that completed or were terminated, 11 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 59 have an industry lead sponsor. The 10 most frequent:
Vertanical GmbH is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Vertanical GmbH has 3 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 59 studies in Low Back Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
The study is divided into four phases: Phase A, B, C and D. All patients who have completed Phase A and for whom the investigator considers further participation to be safe shall begin Phase B. Phases C and D run in parallel, so that patients who have completed Phase B and for whom the investigator considers further participation to be safe can be assigned to one of the two phases.
Phases A and D follow a double-blind, placebo-controlled design, while Phase B and C have an open-label design.
The main goal of Phase A is to demonstrate the efficacy of VER-01 compared to placebo. In Phase B and C the main goal is the investigation of long-term safety of VER-01. In Phase D the primary objective is to demonstrate the maintenance of efficacy of VER-01 on a placebo-controlled basis.
The potential for dependence and abuse will be analyzed in all Phases (A,B,C,D), while the effect of abrupt drug withdrawal of VER-01 will be analyzed in Phase C and D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional for Phase A
a1. Pain intensity averaged at least 4 points on an 11-point NRS (there must be at least 5 pain intensity readings in the morning from the run-in phase)
a2. Willingness not to take any analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during participation in study Phase A (except rescue medication)
a3. Willingness to continue a current non-drug therapy unchanged as planned during participation in Phase A
Additional for Phase B
b1. Previous and complete participation in Phase A until and including Visit A6
b2. Patient wishes to participate voluntarily in the long-term study
b3. From the investigator's point of view, further participation is considered medically safe
b4. Willingness not to take any additional analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during the last three weeks of study Phase B (except rescue medication).
Additional for Phase C
c1. Previous and complete participation in Phase B until and including Visit B10
c2. Patient wishes to participate voluntarily in the long-term study
c3. From the investigator's point of view, further participation is considered medically safe
Additional for Phase D
d1. Previous and complete participation in Phase B until and including Visit B10 (patients received Ver-01 for 26 weeks)
d2. Patient has experienced a pain score improvement of at least 30% in treatment Phase B (mean value of the study week 43 compared to the mean value of the run-in phase, there must be at least four values from study week 43 and five values from the run-in phase)
d3. Patient wishes to participate voluntarily in the study
d4. From the investigator's point of view, further participation is considered medically safe
d5. Willingness not to take any analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during participation in study Phase D (except rescue medication)
d6. Willingness to continue a current non-drug therapy unchanged as planned during study
Exclusion Criteria:
Additional for Phase A:
a1. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture,massage, thermotherapy), which significantly modulates the perception of pain, it was not maintained unchanged for at least eight weeks prior to study participation in Phase A.
Additional for Phase D
d1. Intake of additional analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within 21 days prior to the start of study Phase D (except rescue medication).
d2. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture,massage, thermotherapy) that significantly modulates the perception of pain, it was not maintained unchanged for at least nine weeks prior to the start of study Phase D.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
Drug: VER-01
The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
Other: Placebo
standardised cannabis extract (containing 21 mg THC per gram drug product)
comparator without active ingredient
Phase A: Efficacy based on pain reduction
Change in average pain intensity compared to baseline on an 11-point Numerical Rating Scale (NRS, where 0=no pain to 10=worst pain imaginable) (mean value of study week 15 compared to the mean value of the seven-day run-in phase with daily documentation of pain intensity in the morning).
Time frame: Baseline up to 15 weeks
Phase B: Safety based on occurrence of treatment-related AEs/SAEs
Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs
Time frame: Up to 29 weeks
Phase C: Safety based on occurrence of treatment-related AEs/SAEs
Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs
Time frame: Up to 28 weeks
Phase D: Maintenance of efficacy
Time until treatment failure defined as the time in days from randomization to phase D (R2) until the first day of treatment failure. Treatment failure is assessed by the daily calculated seven-day mean value of the pain score (11 point Numerical Rating Scale, NRS, where 0=no pain to 10=worst pain imaginable) in the morning during the treatment period, which must have deteriorated by at least 20% and at least one point compared to baseline (mean value of study week 43). The first day of treatment failure is then the earliest day within this seven-day time window to which this criterion applies as a single day. Furthermore, treatment failure is defined as a premature discontinuation of treatment for selected reasons.
Time frame: Up to 4 weeks (from date of randomization R2 until the first day of treatment failure)
Phase A, B, C, D: Mean change in neuropathic pain
Absolute change compared to baseline (day1) Neuropathic Pain Symptom Inventory (NPSI) total score at the end of each treatment phase in patients with neuropathic pain
Time frame: Day 1, day 106, day 309, day 351, day 505
Phase A, B, C, D: Change in pain intensity in the morning, as well as in the morning and evening
Absolute changes from baseline in mean pain intensity at the end of each treatment phase measured in the morning (primary endpoint of Phase A) or morning and evening on an 11-point Numerical Rating Scale (NRS, where 0=no pain to 10=worst pain imaginable)
Time frame: Baseline up to 72 weeks
Phases A, B, C and D: Pain responders (30 percent and 50 percent) in the morning, as well as in the morning and evening
The number and proportion of 30 percent and 50 percent pain responders in the morning, and morning and evening at the end of each treatment phase.
Time frame: Baseline up to 72 weeks
Phases A, B, C and D: Sleep quality (NRS)
The absolute change from baseline in mean sleep quality at the end of each treatment phase measured on an 11-point Numerical Rating Scale (NRS, where 0=not impacted to 10=completely impacted)
Time frame: Baseline up to 72 weeks
Phase A: Sleep quality (MOS-SS)
Absolute changes from baseline of sleep quality measured by Medical Outcomes Study Sleep Scale (MOS-SS) per survey point
Time frame: Day 1, Day 22, Day 50, Day 78, Day 106
Phase A: Intake of rescue and concomitant medication
Cumulative dose of rescue medication taken in Phase A
Time frame: Up to 16 weeks
Phase D: Intake of rescue and concomitant medication
Cumulative dose of rescue medication taken in Phase D
Time frame: Up to 6 weeks
Phases A, B, C and D: Depression Anxiety Stress Scales (DASS)
Scores and absolute changes from baseline of depression, anxiety and stress levels measured by the DASS (where 0=did not apply to me at all to 3=affected me very greatly or most of the time) per time point of assessment
Time frame: Baseline up to 72 weeks
Phases A, B, C and D: Global assessment of symptoms (patient global impression of change, PGIC)
Percentage of patients by category of the global assessment of symptoms (PGIC, 7-point Likert scale where 0=very much better to 6=very much worse) by the patient per survey point
Time frame: Day 106, day 309, day 491, day 337
Phases A, B, C and D: Satisfaction with the treatment result - patient
Percentage of patients by category of the satisfaction with the treatment outcome (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the patient per survey point
Time frame: Day 106, day 309, day 491, day 337
Phases A, B, C and D: Satisfaction with the treatment result - investigator
Percentage of patients by category of satisfaction with the treatment outcome (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the investigator per survey point.
Time frame: Day 106, day 309, day 491, day 337
Phases A, B, C and D: Satisfaction with tolerability - patient
Percentage of patients by category of satisfaction with the tolerability (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the patient per survey point
Time frame: Day 106, day 309, day 491, day 337
Phase A: Safety and adverse reactions
Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs
Time frame: Up to 16 weeks
Phase D: Safety and adverse reactions
Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs
Time frame: Up to 6 weeks
Phases A, B, C and D: Quality of life scores (Short Form 36, SF-36)
Scores in quality of life measured per survey point
Time frame: Day 1, day 22, day 50, day 78, day 106, day 309, day 491, day 337
Phases A, B, C and D: Quality of life absolute changes (Short Form 36, SF-36)
Absolute changes in quality of life from baseline (day 1) measured per survey point
Time frame: Day 1, day 22, day 50, day 78, day 106, day 309, day 491, day 337
Phase A: Scores in bodily function and impairment due to low back pain (Roland Morris Disability Questionnaire, RMD)
Scores in bodily function and impairment due to low back pain assessed by the RMD per survey point
Time frame: Day 1, day 22, day 106
Phase A: Absolute changes in bodily function and impairment due to low back pain(Roland Morris Disability Questionnaire, RMD)
Absolute changes in bodily function and impairment due to low back pain assessed by the RMD per survey point
Time frame: Day 1, day 22, day 106
Phases A, B, C and D: Addiction (Addiction Behaviors Checklist ,ABC)
The absolute number of positive answers of the ABC
Time frame: Day 22, day 50, day 78, day 106, day 127, day 183, day 239, day 309, day 365, day 421, day 491, day 337
Phase C: Diagnosis of substance dependence ICD-10 (International Statistical Classification of Diseases and Related Health Problems)
The absolute number of positive answers according to the German Bundesärztekammer (2007) is summarized descriptively according to the standard for continuous parameters.
Time frame: Day 491
Phase A, B, C and D: Adverse events (AEs)
Occurrence of AEs/SAEs
Time frame: Through study completion, up to 72 weeks
Phase C: Withdrawal symptoms (Cannabis Withdrawal Scale, CWS)
Sum scores for intensity and functional impairment are descriptively analysed according to Allsop et al.
Time frame: Up to 2 weeks
Phase D: Withdrawal symptoms (Cannabis Withdrawal Scale, CWS)
Sum scores for intensity and functional impairment are descriptively analysed according to Allsop et al.
Time frame: Up to 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Mar 2024, 32 months.
Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VER-01
Vertanical GmbH